1. Most Discussed
  2. Gainers & Losers
RMD $14.67


  1. jthunder

    307 Posts.

    ResMed Inc (ASX:RMD), a leading manufacturer and developer of
    products for the diagnosis, treatment, and management of
    sleep-disordered breathing (SDB), announced the release of compelling
    new clinical data on the effects of nasal Continuous Positive Airway
    Pressure (nCPAP) treatment on blood pressure reduction in patients
    with sleep apnea. The article appears in the current issue of
    Circulation; the study was performed by Doctor Heinrich Becker and
    colleagues at both the Philipps-University in Marburg Germany and the
    University of Sydney, Australia.

    There are now convincing published data demonstrating that sleep
    apnea causes hypertension (high blood pressure). Recently published
    studies have demonstrated significant falls in daytime blood pressure
    in patients using CPAP at night. The study confirms and extends the
    findings of previous research. In the current study, effective nCPAP
    reduced mean blood pressure by 10mm of mercury (with a standard
    deviation of 11mm) in a group of patients with sleep apnea versus a
    group of patients who were treated with ineffective nCPAP therapy.
    Although the patients' sleep apnea index was halved on the
    ineffective therapy arm, there was no change in blood pressure with
    time on treatment. This implies that unless CPAP levels are adequate
    the associated improvement in cardiovascular morbidity is not
    present. The treatment period was longer than in previous studies,
    and the fall in blood pressure in the effectively treated nCPAP group
    was higher than previously demonstrated. "Previous studies have shown
    only minor treatment effects due to methodological limitations. Using
    continuous blood pressure measurement we were able to show a huge and
    highly clinically significant effect on blood pressure. These results
    are very exciting," Dr Becker commented about the study.

    This study is another very important milestone in the area of the
    effect of SDB on cardiovascular disease, and demonstrates how
    treatment of SDB may positively impact cardiovascular health. This
    study estimated that the reduction in blood pressure seen would
    decrease coronary heart disease risk by 37%, and stroke risk by 56%,
    which would be an enormous benefit to both patients and health care
    costs. According to the American Heart Association, 50 million
    Americans suffer from hypertension. Approximately 15% of these have
    drug resistant hypertension. And it is estimated that 45% of people
    with hypertension have SDB while 83% of patients with drug resistant
    hypertension have SDB.

    ResMed is a leading manufacturer of medical equipment for the
    diagnosis, treatment, and management of sleep-disordered breathing
    (SDB). We are dedicated to improving awareness among patients and
    healthcare professionals of the potentially serious health
    consequences of untreated SDB and to developing innovative technology
    to improve the lives of those who suffer from this condition. More
    information about ResMed can be found at www.resmed.com.

    Further information can be obtained by contacting Wal Flicker at
    ResMed Inc San Diego at country code 1 (858) 746-2211 or by
    contacting the article's principal author, Dr Heinrich Becker at
    [email protected]

Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.


Thank you for visiting HotCopper

We have detected that you are running ad blocking software.

HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.